TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Bio-Path Holdings ( (BPTH) ) just unveiled an update.
Bio-Path Holdings is currently seeking financing to support a planned turnaround, which includes updating their finance team, engaging new PCAOB auditors, hiring investment bankers to review their biotech portfolio, and pursuing strategic mergers and acquisitions. The company acknowledges the uncertainty in raising the necessary capital and the potential impact on their ability to continue operations and remain listed on public trading platforms.
The most recent analyst rating on (BPTH) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Bio-Path Holdings stock, see the BPTH Stock Forecast page.
Spark’s Take on BPTH Stock
According to Spark, TipRanks’ AI Analyst, BPTH is a Underperform.
Bio-Path Holdings’ stock is significantly challenged by poor financial performance, characterized by no revenue and high cash burn. The technical indicators also suggest a bearish trend. However, the promising pre-clinical results offer a glimmer of hope for future prospects. The negative P/E ratio and lack of dividend yield further contribute to a low valuation score. Overall, the stock is risky, with financial sustainability being a major concern.
To see Spark’s full report on BPTH stock, click here.
More about Bio-Path Holdings
Average Trading Volume: 66,604
Technical Sentiment Signal: Strong Sell
Current Market Cap: $714.5K
See more insights into BPTH stock on TipRanks’ Stock Analysis page.